AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

55.08USD
10:59pm IST
Price Change (% chg)

$0.02 (+0.04%)
Prev Close
$55.06
Open
$54.84
Day's High
$55.11
Day's Low
$54.68
Volume
801,580
Avg. Vol
1,825,225
52-wk High
$58.27
52-wk Low
$42.25

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $87,674.88
Shares Outstanding (Mil.): 1,592.35
Dividend: 0.42
Yield (%): 3.05

Financials

  ABBV.N Industry Sector
P/E (TTM): 21.24 32.90 33.74
EPS (TTM): 2.59 -- --
ROI: 19.03 18.79 18.03
ROE: 95.03 19.42 18.77
Search Stocks

Drug company won't appeal gay rights ruling to top U.S. court

SAN FRANCISCO, Aug 5 - AbbVie Inc will not seek U.S. Supreme Court review of a ruling in a lawsuit brought against the company that extended landmark constitutional protections for gays and lesbians, a company spokesman said on Tuesday.

06 Aug 2014

UPDATE 3-AbbVie profit beats estimates on surging Humira sales

July 25 - AbbVie Inc, which last week announced plans to buy Dublin-based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly earnings on surging sales of its Humira treatment for rheumatoid arthritis.

25 Jul 2014

U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal

LONDON - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain. | Video

19 Jul 2014

U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 bln deal

LONDON - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain.

19 Jul 2014

AbbVie’s Shire merger backed with 13.5 billion pound bridge loan

LONDON - U.S. drugmaker AbbVie’s 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

RLPC-AbbVie's Shire merger backed with 13.5 bln stg bridge loan

LONDON, July 18 - U.S. drugmaker AbbVie's 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

AbbVie CEO says tax is not primary reason for buying Shire

LONDON - Pharmaceutical firm AbbVie's chairman and chief executive said tax benefits were not the main reason it bought London-listed Shire .

18 Jul 2014

AbbVie CEO says tax is not primary reason for buying Shire

LONDON, July 18 - Pharmaceutical firm AbbVie's chairman and chief executive said tax benefits were not the main reason it bought London-listed Shire.

18 Jul 2014

Deals of the day- Mergers and acquisitions

(Adds Abbvie, Allergan, TRW Auto, Telefonica, Bingham McCutchen, Fred's, GTECH, Slovak Telekom, Cliffs Natural, Rosneft, Woolworths, Koncar, Dong Energy ; updates Fiat Chrysler)

18 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $104.16 +0.95
Pfizer Inc. (PFE.N) $28.88 -0.01
Novartis AG (NOVN.VX) CHF81.10 +0.25
Merck & Co., Inc. (MRK.N) $59.08 -0.40
Roche Holding Ltd. (ROG.VX) CHF265.80 +0.30
Abbott Laboratories (ABT.N) $42.38 +0.24
Eli Lilly and Co (LLY.N) $62.13 +0.12

Earnings vs. Estimates

Search Stocks